In particular, PgR loss promotes BC cell resistance to SERMs, but not to therapies that act by reducing blood estrogen concentration, such as aromatase inhibitors, or drugs that bind ERα and stimulate its degradation, such as SERDs [33]. Here, ESR1 is linked to breast cancer.